Here’s how TECVAYLI® works to fight multiple myeloma
TECVAYLI® is a type of treatment known as a bispecific antibody, which means it works by helping your immune system locate and target the multiple myeloma cells in your body.
- One side of TECVAYLI® binds to proteins called CD3, which are found on your T-cells
- The other side binds to proteins called BCMA, which are found on multiple myeloma cells (as well as some healthy cells)
- In doing so, TECVAYLI® is able to activate the T-cells in your immune system to destroy the multiple myeloma cells in your body
TECVAYLI® attaches to 2 different cells to fight multiple myeloma
By binding to BCMA and CD3, TECVAYLI® helps the immune system recognize the
multiple myeloma cell and destroy it.
If you experience a relapse on another treatment, you still have options
It is common for patients with multiple myeloma to experience a relapse, which means the disease initially responds to treatment but then progresses. Multiple myeloma is considered refractory when it fails to respond to treatment and then progresses.
If your multiple myeloma is relapsed or refractory, ask your healthcare provider if TECVAYLI® is right for you
TECVAYLI® is a prescription medicine for adults with multiple myeloma whose cancer has come back or did not respond to treatment and who have already received at least 4 prior treatment regimens, including:
- a proteasome inhibitor
- an immunomodulatory agent, and
- an anti-CD38 monoclonal antibody
TECVAYLI® was approved based on patient responses. There are ongoing studies to confirm the clinical benefit of TECVAYLI®.
It is not known if TECVAYLI® is safe and effective in children.